Associate Professor of Medicine, University Wash
Oncology
Dr. Mary L. Disis, MD
|
|
Give Review
Mary Disis practices Oncology. Mary Disis is a published physician. He has 85 papers published. The most current publication "Current methods of epitope identification for cancer vaccine design."
Publications
- Current methods of epitope identification for cancer vaccine design.
- Designing vaccines to prevent breast cancer recurrence or invasive disease.
- Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.
- Elimination of IL-10-Inducing T-Helper Epitopes from an IGFBP-2 Vaccine Ensures Potent Antitumor Activity.
- Expanding assessments of translational research programs: supplementing metrics with value judgments.
- Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activation.
- A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease.
- Can immunity to breast cancer eliminate residual micrometastases?
- CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer.
- HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.
- Therapeutic vaccines for ovarian cancer.
- Evaluation of Cancer Immunity in Mice.
- The invisible arm of immunity in common cancer chemoprevention agents.
- Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK.
- Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.
- Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in pre-diagnostic breast cancer sera.
- Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
- Defining the Critical Hurdles in Cancer Immunotherapy.
- VTX-2337 Is a Novel TLR8 Agonist that Activates NK Cells and Augments ADCC.
- TLR2 agonist PSK activates human NK cells and enhances the anti-tumor effect of HER2-targeted monoclonal antibody therapy.
- Therapeutic Cancer Vaccines and Translating Vaccinomics Science to the Global Health Clinic: Emerging Applications Toward Proof of Concept.
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
- Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival.
- TNM staging in colorectal cancer: T is for T cell and M is for memory.
- Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.
- Phase I studies of drug combinations.
- Immune regulation of cancer.
- Wouldn’t we all like to be a little more LEAN?
- Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
- The ultimate in cancer chemoprevention: cancer vaccines.
- The road we must take: multidisciplinary team science.
- A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a che...
- Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment.
- Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
- Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
- Toward a stem cell gene therapy for breast cancer.
- Use of tumour-responsive T cells as cancer treatment.
- Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.
- An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.
- Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer.
- An analytical workflow for investigating cytokine profiles.
- Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.
- The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity.
- Immune modulation as a therapeutic strategy for non-small-cell lung cancer.
- Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
- Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature.
- Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitu...
- Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
- Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers.
- The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens.
- Immunoediting of cancers may lead to epithelial to mesenchymal transition.
- IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
- 10th Biennial Helene Harris Memorial Trust meeting.
- Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
- Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
- Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal ant...
- Laboratory analysis of T-cell immunity.
- Global role of the immune system in identifying cancer initiation and limiting disease progression.
- Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy.
- Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells.
- Molecular targeting with cancer vaccines.
- Clinical use of subcutaneous G-CSF or GM-CSF in malignancy.
- Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
- Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.
- Conflicts of interest in translational research.
- Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
- Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.
- Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.
- Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
- Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.
- Clinical studies of vaccines targeting breast cancer.
- Future directions in the management of ovarian cancer.
- Immunologic principles and immunotherapeutic approaches in ovarian cancer.
- Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia.
- Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells.
- Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.
- Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
- Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
- Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
- Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.
- Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.
- Issues on Clinical Applications of Cancer Vaccines.
Schools
University of Nebraska College of Medicine
University Of Illinois
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Choice Health PPO
- Coop Core
- Connect
- MultiPlan PPO
- Heritage Plus
- Heritage Signature
- Personal Option EPO
- Preferred Provider Network PPN
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Education
-
University of Washington
Hospital
-
Seattle Children's Hospital -
University of Washington Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Johnnie J. Orozco, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig R. Nichols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elahe A. Mostaghel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick R. Appelbaum, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kim A. Margolin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul V. O'Donnell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Min S. Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian G. Till, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina S. Baik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derek L. Stirewalt, MD
This Doctor is OpenDoctor Recommended.
|